Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Radian Group Inc    RDN

Delayed Quote. Delayed  - 07/29 10:03:07 pm
12.9 USD   +1.42%
07/28 RADIAN : Strong Quarter at Mortgage Insurer Radian
07/28 RADIAN : misses 2Q profit forecasts
07/28 RADIAN : Announces Second Quarter 2016 Financial Results
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Radian Group Inc : Radian Group Inc. And Keryx Biopharmaceuticals News: (NYSE: RDN), (NASDAQ; KERX)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 07:30am CEST

New York (April 22nd, 2013) - Radian Group Inc. (NYSE: RDN) announced that it will hold a conference call on Wednesday, May 1, 2013, at 11:00 a.m. Eastern time to discuss the company?s first quarter results, which will be announced prior to the market open on the same day.

Radian Group Inc. (RDN), headquartered in Philadelphia, provides private mortgage insurance and related risk mitigation products and services to mortgage lenders nationwide through its principal operating subsidiary, Radian Guaranty Inc. These services help promote and preserve homeownership opportunities for homebuyers, while protecting lenders from default-related losses on residential first mortgages and facilitating the sale of low-downpayment mortgages in the secondary market.

Find out more on RDN here:

http://www.wallstreetscoop.net/market-scan/?symbol=RDN


Keryx Biopharmaceuticals (NASDAQ:KERX) traded at $ 8.03 in the last session, which is +0.42 (5.52%). The stock has a Range of 7.58 - 8.06. The stock has a 52 week low and high of 1.30 - 9.98 respectively. The stock has a Market Cap of 655.90M. The stock traded a volume of 2.32M. The stock has a 30 day average volume of 2.74M.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.

Find out if KERX could maintain its gaining momentum here:

http://www.wallstreetscoop.net/market-scan/?symbol=KERX


About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop
info@wallstreetscoop.net
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RADIAN GROUP INC
07/28 RADIAN : Strong Quarter at Mortgage Insurer Radian
07/28 RADIAN GROUP INC : Results of Operations and Financial Condition, Financial Stat..
07/28 RADIAN : misses 2Q profit forecasts
07/28 RADIAN : Announces Second Quarter 2016 Financial Results
07/20 RADIAN : Shares of Radian Group (RDN) Rally 9.57%
07/19 RADIAN : Clayton Holdings Offers New Underwriting Solution For Fix And Flip Fina..
07/18 RADIAN : Short Interest Increased by 9.75%
07/15 RADIAN : to Webcast Second Quarter Conference Call on July 28, 2016
07/13 RADIAN GROUP INC : Other Events (form 8-K)
07/12 RADIAN : Shorted Shares Increased 9.75% After Market Selling
More news
Sector news : Property & Casualty Insurance - NEC
07/30DJNextEra Clinches $18.4 Billion Deal -- WSJ
07/29DJNextEra to Buy Energy Future's Oncor in $18.4 Billion Deal -- 5th Update
07/29DJNextEra to Buy Energy Future's Oncor in $18.4 Billion Deal -- 4th Update
07/29DJSAMPO OYJ SAMPO PLC : Disclosure Under Chapter 9 Section 5 Of The Securities Mar..
07/29DJNextEra to Buy Energy Future's Oncor in $18.4 Billion Deal
More sector news : Property & Casualty Insurance - NEC
News from SeekingAlpha
07/28 Radian Group's (RDN) CEO S.A. Ibrahim on Q2 2016 Results - Earnings Call Tran..
07/28 Radian bull finds a lot to like with Q2 report
07/28 More on Radian's inline Q2
07/28 Radian Group EPS in-line, beats on revenue
07/27 Notable earnings before Thursday?s open
Advertisement
Financials ($)
Sales 2016 906 M
EBIT 2016 580 M
Net income 2016 329 M
Debt 2016 -
Yield 2016 0,08%
P/E ratio 2016 8,51
P/E ratio 2017 7,11
Capi. / Sales 2016 3,05x
Capi. / Sales 2017 2,82x
Capitalization 2 764 M
More Financials
Chart RADIAN GROUP INC
Duration : Period :
Radian Group Inc Technical Analysis Chart | RDN | US7502361014 | 4-Traders
Full-screen chart
Technical analysis trends RADIAN GROUP INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 17,0 $
Spread / Average Target 31%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Sanford A. Ibrahim Chief Executive Officer & Director
Herbert Wender Non-Executive Chairman
J. Franklin Hall Chief Financial Officer & Executive Vice President
Richard I. Altman Chief Information Officer & Executive VP
David Charles Carney Independent Non-Employee Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
RADIAN GROUP INC-3.66%2 764
BERKSHIRE HATHAWAY INC..9.20%355 383
TRAVELERS COMPANIES IN..2.98%33 504
TOKIO MARINE HOLDINGS ..-13.80%29 977
ALLSTATE CORP10.05%25 581
SAMPO OYJ-20.09%23 149
More Results